Pivotal role of PAI-1 in a murine model of hepatic vein thrombosis
- 1 January 2006
- journal article
- Published by American Society of Hematology in Blood
- Vol. 107 (1) , 132-134
- https://doi.org/10.1182/blood-2005-07-2681
Abstract
Hepatic veno-occlusive disease (VOD) is a common complication of high-dose chemotherapy associated with bone marrow transplantation. While the pathogenesis of VOD is uncertain, plasminogen activator inhibitor-1 (PAI-1) has emerged as a diagnostic marker and predictor of VOD in humans. In this study, we investigated the role of PAI-1 in a murine model of VOD produced by long-term nitric oxide synthase inhibition using L-NAME. After 6 weeks, wild-type (WT) mice developed extensive fibrinoid hepatic venous thrombi and biochemical evidence of hepatic injury and dysfunction. In contrast, PAI-1–deficient mice were largely protected from the development of hepatic vein thrombosis. Furthermore, WT mice that received tiplaxtinin, an antagonist of PAI-1, were effectively protected from L-NAME–induced thrombosis. Taken together, these data indicate that NO and PAI-1 play pivotal and antagonistic roles in hepatic vein thrombosis and that PAI-1 is a potential target in the prevention and treatment of VOD in humans.Keywords
This publication has 28 references indexed in Scilit:
- Pharmacological Inhibition and Genetic Deficiency of Plasminogen Activator Inhibitor-1 Attenuates Angiotensin II/Salt-Induced Aortic RemodelingArteriosclerosis, Thrombosis, and Vascular Biology, 2005
- Tiplaxtinin, a Novel, Orally Efficacious Inhibitor of Plasminogen Activator Inhibitor-1: Design, Synthesis, and Preclinical CharacterizationJournal of Medicinal Chemistry, 2004
- Decreased hepatic nitric oxide production contributes to the development of rat sinusoidal obstruction syndromeHepatology, 2003
- Decreased Hepatic Nitric Oxide Production Contributes to the Development of Rat Sinusoidal Obstruction SyndromeHepatology, 2003
- Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cellsLeukemia, 2003
- INHIBITION OF NITRIC OXIDE SYNTHASE AS A POTENTIAL THERAPEUTIC TARGETAnnual Review of Pharmacology and Toxicology, 1999
- Natriuretic Factors and Nitric Oxide Suppress Plasminogen Activator Inhibitor-1 Expression in Vascular Smooth Muscle CellsArteriosclerosis, Thrombosis, and Vascular Biology, 1998
- Modulation of plasminogen activator inhibitor-1 in vivo: A new mechanism for the anti-fibrotic effect of renin-angiotensin inhibitionKidney International, 1997
- Cellular Target of Cyclophosphamide Toxicity in the Murine Liver: Role of Glutathione and Site of Metabolic ActivationHepatology, 1996
- Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization.Journal of Clinical Investigation, 1993